Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Protocol Title: An Open Label, Multi-centre Phase 1/2a Study of Modified and Unmodified Autologous Tumour Infiltrating Lymphocytes (TIL) in Patients With Platinum-resistant Ovarian Cancer

NCT04389229 is registered in ClinicalTrials.gov with Immetacyte Ltd as lead sponsor.

NCT NCT04389229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04389229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Protocol Title: An Open Label, Multi-centre Phase 1/2a Study of Modified and Unmodified Autologous Tumour Infiltrating Lymphocytes (TIL) in Patients With Platinum-resistant Ovarian Cancer
Lead sponsor
Immetacyte Ltd
Phase
Phase 1/2
Overall status
Withdrawn
Start date
July 1, 2020
Completion date
July 31, 2025
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer metastatic